scholarly journals STEM-16. DUAL INHIBITION OF PROTEIN ARGININE METHYLTRANSFERASE 5 AND PROTEIN PHOSPHATASE 2A ENHANCES THE ANTI-TUMOR EFFICACY IN PRIMARY GLIOBLASTOMA NEUROSPHERES

2019 ◽  
Vol 21 (Supplement_6) ◽  
pp. vi237-vi237
Author(s):  
Hannah Sur ◽  
Arunakumar Gangaplara ◽  
Xiang Wang ◽  
Abhik Ray-Chaudhury ◽  
Zhengping Zhuang ◽  
...  
Keyword(s):  
Cell Cycle ◽  
Combination Therapy ◽  
Tumor Cells ◽  
Protein Phosphatase ◽  
Protein Phosphatase 2A ◽  
Protein Arginine Methyltransferase ◽  
Arginine Methyltransferase ◽  
Pp2a Activity ◽  
Phosphatase 2A ◽  
Protein Arginine Methyltransferase 5

Abstract INTRODUCTION Glioblastoma (GBM) is the most common malignant primary brain tumor and has a heterogeneous tumor cell population. The median survival of GBM patients is less than two years with current multi-model therapy of maximal surgical resection followed by chemotherapy, radiation and tumor treating fields. Protein Arginine Methyltransferase 5 (PRMT5) regulates cellular functions through symmetric di-methylation of arginine residues of histone and non-histone proteins. Our recent findings show that PRMT5 is overexpressed in GBM; its inhibition causes apoptosis and senescence of mature and immature GBM tumor cells respectively. Protein Phosphatase 2A (PP2A), a serine-threonine phosphatase, is associated with senescent tumor cells that contribute to therapy resistance; LB100 is a first-in-class small molecule inhibitor of PP2A that can sensitize tumor cells that are chemo- and radiation-therapy resistant. In this study, using patient-derived primary GBM neurospheres (GBMNS), we tested the anti-GBM effect of concurrent PRMT5 and PP2A inhibition. METHODS Patient-derived primary GBM neurospheres transfected with PRMT5 target-specific siRNA were treated with LB100 and subjected to in vitro assays such as proliferation assay, cell cycle analysis, cytotoxicity assay, PP2A activity and western blot. RESULTS LB100 treatment significantly reduced the viability of PRMT5-depleted GBM cells as compared to PRMT5 intact cells. LB100 caused G1 cell cycle arrest through inactivation of Rb protein; this effect is further enhanced in combination with PRMT5-depletion. Combination therapy also increased the expression of phospho-MLKL; Necrostatin-1 rescued PRMT5-depleted cells from the cytotoxic effects of LB100 indicating that necroptosis caused the enhanced cytotoxicity in combination therapy. We also found that PRMT5-depletion increased the PP2A activity in GBM neurospheres. CONCLUSION Combining the PRMT5 inhibition and PP2A inhibition produced greater antitumor effects than with PRMT5 inhibition alone.

scholarly journals Inhibiting protein phosphatase 2A increases the antitumor effect of protein arginine methyltransferase 5 inhibition in models of glioblastoma

2021 ◽  
Author(s):  
Yoshihiro Otani ◽  
Hannah Sur ◽  
Guruprasad Rachaiah ◽  
Sriya Namagiri ◽  
Ashis Chowdhury ◽  
...  
Keyword(s):  
Combination Therapy ◽  
Tumor Cells ◽  
Protein Phosphatase ◽  
Protein Phosphatase 2A ◽  
Xenograft Model ◽  
Protein Arginine Methyltransferase ◽  
Arginine Methyltransferase ◽  
Pp2a Activity ◽  
Phosphatase 2A

Abstract Background Despite multi-model therapy of maximal surgical resection, radiation, chemotherapy, and tumor treating fields, the median survival of Glioblastoma (GBM) patients is less than 15 months. Protein Arginine Methyltransferase 5 (PRMT5) catalyzes the symmetric di-methylation of arginine residues and is overexpressed in GBM. Inhibition of PRMT5 causes senescence in stem-like GBM tumor cells. LB100, a first-in-class small molecular inhibitor of Protein Phosphatase 2A (PP2A) can sensitize therapy-resistant tumor cells. Here, we tested the anti-GBM effect of concurrent PRMT5 and PP2A inhibition. Methods Patient-derived primary GBM neurospheres (GBMNS), transfected with PRMT5 target-specific siRNA were treated with LB100 and subjected to in vitro assays including PP2A activity and western blot. The intracranial mouse xenograft model was used to test the in vivo antitumor efficacy of combination treatment. Results We found that PRMT5-depletion increased PP2A activity in GBMNS. LB100 treatment significantly reduced the viability of PRMT5-depleted GBMNS compared to PRMT5 intact GBMNS. LB100 enhanced G1 cell cycle arrest induced by PRMT5-depletion. Combination therapy also increased the expression of phospho-MLKL. Necrostatin-1 rescued PRMT5-depleted cells from the cytotoxic effects of LB100, indicating that necroptosis caused the enhanced cytotoxicity of combination therapy. In the in vivo mouse tumor xenograft model, LB100 treatment combined with transient depletion of PRMT5 significantly decreased tumor size and prolonged survival, while LB100 treatment alone had no survival benefit. Conclusion Overall, combined PRMT5 and PP2A inhibition had significantly greater antitumor effects than PRMT5 inhibition alone.

scholarly journals STEM-23. INHIBITING PROTEIN PHOSPHATASE 2A INCREASES THE ANTITUMOR EFFECT OF PROTEIN ARGININE METHYLTRANSFERASE 5 INHIBITION IN MODELS OF GLIOBLASTOMA

2020 ◽  
Vol 22 (Supplement_2) ◽  
pp. ii201-ii201
Author(s):  
Yeshavanth Kumar Banasavadi Siddegowda ◽  
Hannah Sur ◽  
Yoshihiro Otani ◽  
Guruprasad Rachaiah ◽  
Sriya Namagiri ◽  
...  
Keyword(s):  
Combination Therapy ◽  
Tumor Cells ◽  
Protein Phosphatase ◽  
Protein Phosphatase 2A ◽  
Xenograft Model ◽  
Protein Arginine Methyltransferase ◽  
Arginine Methyltransferase ◽  
Pp2a Activity ◽  
Phosphatase 2A

Abstract BACKGROUND: Despite multi-model therapy of maximal surgical resection, radiation, chemotherapy, and tumor treating fields, median survival of Glioblastoma (GBM) patients is less than two years. Protein Arginine Methyltransferase 5 (PRMT5) catalyzes the symmetric di-methylation of arginine residues and is overexpressed in GBM. Inhibition of PRMT5 causes senescence of immature GBM tumor cells. LB100, first-in-class small molecule inhibitor of Protein Phosphatase 2A (PP2A) can sensitize therapy-resistant tumor cells. Here, we tested the anti-GBM effect of concurrent PRMT5 and PP2A inhibition. Methods: Patient-derived primary GBM neurospheres (GBMNS), transfected with PRMT5 target-specific siRNA were treated with LB100 and subjected to in vitro assays including PP2A activity and western blot. The intracranial mouse xenograft model was used to test the in vivo antitumor efficacy of combination treatment. Results: We found that PRMT5-depletion increased PP2A activity in GBMNS. LB100 treatment significantly reduced the viability of PRMT5-depleted GBMNS compared to PRMT5 intact GBMNS. LB100 enhanced the G1 cell cycle arrest induced by PRMT5-depletion. Combination therapy also increased the expression of phospho-MLKL. Necrostatin-1 rescued PRMT5-depleted cells from the cytotoxic effects of LB100, indicating that necroptosis caused the enhanced cytotoxicity of combination therapy. In the in vivo mouse tumor xenograft model, LB100 treatment combined with transient depletion of PRMT5 significantly decreased tumor size and prolonged mice survival, while LB100 treatment alone had no survival benefit. Conclusion: Overall, combined PRMT5 and PP2A inhibition had significantly greater antitumor effects than PRMT5 inhibition alone.

scholarly journals Characterization of the Aalpha and Abeta subunit isoforms of protein phosphatase 2A: differences in expression, subunit interaction, and evolution

2003 ◽  
Vol 369 (2) ◽  
pp. 387-398 ◽  
Author(s):  
Jin ZHOU ◽  
Huong T. PHAM ◽  
Ralf RUEDIGER ◽  
Gernot WALTER
Keyword(s):  
Cell Cycle ◽  
Cell Lines ◽  
Protein Phosphatase ◽  
Protein Phosphatase 2A ◽  
Expression Patterns ◽  
Simian Virus 40 ◽  
Polyoma Virus ◽  
Tumour Antigen ◽  
Small Tumour ◽  
Phosphatase 2A

Protein phosphatase 2A (PP2A) is very versatile owing to a large number of regulatory subunits and its ability to interact with numerous other proteins. The regulatory A subunit exists as two closely related isoforms designated Aα and Aβ. Mutations have been found in both isoforms in a variety of human cancers. Although Aα has been intensely studied, little is known about Aβ. We generated Aβ-specific antibodies and determined the cell cycle expression, subcellular distribution, and metabolic stability of Aβ in comparison with Aα. Both forms were expressed at constant levels throughout the cell cycle, but Aα was expressed at a much higher level than Aβ. Both forms were found predominantly in the cytoplasm, and both had a half-life of approx. 10h. However, Aα and Aβ differed substantially in their expression patterns in normal tissues and in tumour cell lines. Whereas Aα was expressed at similarly high levels in all tissues and cell lines, Aβ expression varied greatly. In addition, in vivo studies with epitope-tagged Aα and Aβ subunits demonstrated that Aβ is a markedly weaker binder of regulatory B and catalytic C subunits than Aα. Construction of phylogenetic trees revealed that the conservation of Aα during the evolution of mammals is extraordinarily high in comparison with both Aβ and cytochrome c, suggesting that Aα is involved in more protein—protein interactions than Aβ. We also measured the binding of polyoma virus middle tumour antigen and simian virus 40 (SV40) small tumour antigen to Aα and Aβ. Whereas both isoforms bound polyoma virus middle tumour antigen equally well, only Aα bound SV40 small tumour antigen.

Identification of a protein phosphatase 2A family member that regulates cell cycle progression in Trypanosoma brucei

2014 ◽  
Vol 194 (1-2) ◽  
pp. 48-52 ◽  
Author(s):  
Karen G. Rothberg ◽  
Neal Jetton ◽  
James G. Hubbard ◽  
Daniel A. Powell ◽  
Vidya Pandarinath ◽  
...  
Keyword(s):  
Cell Cycle ◽  
Family Member ◽  
Trypanosoma Brucei ◽  
Protein Phosphatase ◽  
Cell Cycle Progression ◽  
Protein Phosphatase 2A ◽  
Cycle Progression ◽  
Phosphatase 2A

scholarly journals Molecular genetic analysis of Rts1p, a B' regulatory subunit of Saccharomyces cerevisiae protein phosphatase 2A.

1997 ◽  
Vol 17 (6) ◽  
pp. 3242-3253 ◽  
Author(s):  
Y Shu ◽  
H Yang ◽  
E Hallberg ◽  
R Hallberg
Keyword(s):  
Saccharomyces Cerevisiae ◽  
Cell Cycle ◽  
High Temperatures ◽  
Protein Phosphatase ◽  
Protein Phosphatase 2A ◽  
Molecular Genetic Analysis ◽  
Regulatory Subunit ◽  
Temperature Sensitive ◽  
Checkpoint Control ◽  
Phosphatase 2A

The Saccharomyces cerevisiae gene RTS1 encodes a protein homologous to a variable B-type regulatory subunit of the mammalian heterotrimeric serine/threonine protein phosphatase 2A (PP2A). We present evidence showing that Rts1p assembles into similar heterotrimeric complexes in yeast. Strains in which RTS1 has been disrupted are temperature sensitive (ts) for growth, are hypersensitive to ethanol, are unable to grow with glycerol as their only carbon source, and accumulate at nonpermissive temperatures predominantly as large-budded cells with a 2N DNA content and a nondivided nucleus. This cell cycle arrest can be overcome and partial suppression of the ts phenotype of rts1-null cells occurs if the gene CLB2, encoding a Cdc28 kinase-associated B-type cyclin, is expressed on a high-copy-number plasmid. However, CLB2 overexpression has no suppressive effects on other aspects of the rts1-null phenotype. Expression of truncated forms of Rts1p can also partially suppress the ts phenotype and can fully suppress the inability of cells to grow on glycerol and the hypersensitivity of cells to ethanol. By contrast, the truncated forms do not suppress the accumulation of large-budded cells at high temperatures. Coexpression of truncated Rts1p and high levels of Clb2p fully suppresses the ts phenotype, indicating that the inhibition of growth of rts1-null cells at high temperatures is due to both stress-related and cell cycle-related defects. Genetic analyses show that the role played by Rts1p in PP2A regulation is distinctly different from that played by the other known variable B regulatory subunit, Cdc55p, a protein recently implicated in checkpoint control regulation.

Abstract 229: Novel Plasma Membrane Beta Adrenergic Receptor Resensitization By Protein Phosphatase 2a

Circulation ◽  
2008 ◽  
Vol 118 (suppl_18) ◽  
Author(s):  
Neelakantan T Vasudevan ◽  
Anita Shukla ◽  
Sathyamangla V Naga Prasad
Keyword(s):  
Plasma Membrane ◽  
Protein Phosphatase ◽  
Adrenergic Receptor ◽  
Protein Phosphatase 2A ◽  
Metabolic Labeling ◽  
Specific Expression ◽  
Pp2a Activity ◽  
Pi3k Activity ◽  
Phosphatase 2A

Resensitization of β-adrenergic receptor (βAR) occurs by dephosphorylation of the internalized βAR by protein phosphatase 2A (PP2A) before being recycled back to plasma membrane (PM). Contrary to this classical paradigm, cardiac specific expression of inactive PI3Kγ (PI3Kγ inact ) leads to receptor resensitization at the plasma membrane as measured by adenylyl cyclase activity in mice chronically treated with the agonist. We hypothesized that PI3K activity inhibits PM receptor resensitization. Using cells stably expressing FLAG-β 1 AR alone (single) or along with PI3Kγ inact (double), we show that inhibition of PI3K activity results in novel PM receptor resensitization. Agonist activation of single stables showed significant receptor desensitization as measured by reduced cAMP generation (35.6 ± 4.6 pmol/mg protein). In contrast, double-or wortmannin (Wort, PI3K inhibitor) pre-treated single- stables showed marked generation of cAMP (87.4 ± 3.2 or 83.1 ± 5.7) showing β 1 AR resensitization. Agonist stimulation of metabolically labeled β 1 ARs pre-treated with inhibitors of internalization, sucrose and β-cyclodextrin resulted in accumulation of phosphorylated receptors at the PM, which was abolished with PI3Kγ inact suggesting dephosphorylation of β 1 ARs. Inhibition of PP2A by okadaic acid or Fostriecin resulted in complete loss of β 1 AR resensitization despite the presence of PI3Kγ inact showing that PI3K regulates PP2A activity at the β 1 AR complex. Pre-treatment of single stable cells with Wort resulted in significant increase in β 1 AR-associated phosphatase activity following dobutamine (Dob) treatment (Veh, 4131 ± 14; Dob, 3180 ± 111; Dob + Wort, 17123 ± 680 pmoles/mg protein). Consistently, similar results were obtained in vivo using single transgenic (FLAG-β 1 AR, Veh, 87 ± 12; Dob, 61.7 ± 8.3) and double transgenic (FLAG-β 1 AR and PI3Kγ inact , Veh, 93 ± 9; Dob, 118 ± 6) mice. In vivo metabolic labeling, co-immunoprecipitation and in vitro kinase assays showed that inhibitor of PP2A (I2PP2A) protein as a target of PI3K in regulating PP2A activity at the β 1 AR complex. Indeed, siRNA knock down of I2PP2A results in preservation of β 1 AR function by PM receptor resensitization demonstrating a novel role for PI3K in receptor resensitization. This research has received full or partial funding support from the American Heart Association, AHA Great Rivers Affiliate (Delaware, Kentucky, Ohio, Pennsylvania & West Virginia).

scholarly journals A novel pool of protein phosphatase 2A is associated with microtubules and is regulated during the cell cycle.

1995 ◽  
Vol 128 (6) ◽  
pp. 1131-1144 ◽  
Author(s):  
E Sontag ◽  
V Nunbhakdi-Craig ◽  
G S Bloom ◽  
M C Mumby
Keyword(s):  
Cell Cycle ◽  
Enzymatic Activity ◽  
Protein Phosphatase ◽  
Protein Phosphatase 2A ◽  
S Phase ◽  
Phosphatase 2A ◽  
Spindle Microtubules ◽  
Cycle Dependent ◽  
Cycle Regulation

Immunofluorescence microscopy revealed the presence of protein phosphatase 2A (PP2A) on microtubules in neuronal and nonneuronal cells. Interphase and mitotic spindle microtubules, as well as centrosomes, were all labeled with antibodies against individual PP2A subunits, showing that the AB alpha C holoenzyme is associated with microtubules. Biochemical analysis showed that PP2A could be reversibly bound to microtubules in vitro and that approximately 75% of the PP2A in cytosolic extracts could interact with microtubules. The activity of microtubule-associated PP2A was differentially regulated during the cell cycle. Enzymatic activity was high during S phase and intermediate during G1, while the activity in G2 and M was 20-fold lower than during S phase. The amount of microtubule-bound PP2A remained constant throughout the cell cycle, implying that cell cycle regulation of its enzymatic activity involves factors other than microtubules. These results raise the possibility that PP2A regulates cell cycle-dependent microtubule functions, such as karyokinesis and membrane transport.

Sign in / Sign up

Export Citation Format

Share Document